nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Clindamycin—malaria	0.16	0.268	CbGbCtD
Pimecrolimus—CYP3A4—Sulfadiazine—malaria	0.0919	0.154	CbGbCtD
Pimecrolimus—CYP3A4—Artemether—malaria	0.0781	0.131	CbGbCtD
Pimecrolimus—CYP3A4—Proguanil—malaria	0.0735	0.123	CbGbCtD
Pimecrolimus—CYP3A4—Doxycycline—malaria	0.0696	0.116	CbGbCtD
Pimecrolimus—CYP3A4—Quinine—malaria	0.0473	0.0792	CbGbCtD
Pimecrolimus—CYP3A4—Quinidine—malaria	0.0416	0.0696	CbGbCtD
Pimecrolimus—CYP3A4—Dapsone—malaria	0.0359	0.06	CbGbCtD
Pimecrolimus—MTOR—blood plasma—malaria	0.0114	0.129	CbGeAlD
Pimecrolimus—FKBP1A—blood plasma—malaria	0.0102	0.116	CbGeAlD
Pimecrolimus—Phototoxicity—Dapsone—malaria	0.00961	0.0366	CcSEcCtD
Pimecrolimus—Application site burn—Dapsone—malaria	0.00879	0.0335	CcSEcCtD
Pimecrolimus—Application site burn—Clindamycin—malaria	0.0085	0.0324	CcSEcCtD
Pimecrolimus—Superinfection—Clindamycin—malaria	0.00785	0.0299	CcSEcCtD
Pimecrolimus—Application site erythema—Dapsone—malaria	0.00782	0.0298	CcSEcCtD
Pimecrolimus—Application site erythema—Clindamycin—malaria	0.00756	0.0288	CcSEcCtD
Pimecrolimus—Application site pruritus—Dapsone—malaria	0.00755	0.0287	CcSEcCtD
Pimecrolimus—Application site pruritus—Clindamycin—malaria	0.0073	0.0278	CcSEcCtD
Pimecrolimus—MTOR—hematopoietic system—malaria	0.00628	0.0711	CbGeAlD
Pimecrolimus—Leukaemia—Pentoxifylline—malaria	0.00585	0.0223	CcSEcCtD
Pimecrolimus—FKBP1A—hematopoietic system—malaria	0.00564	0.0639	CbGeAlD
Pimecrolimus—MTOR—kidney—malaria	0.00514	0.0582	CbGeAlD
Pimecrolimus—FKBP1A—kidney—malaria	0.00463	0.0524	CbGeAlD
Pimecrolimus—MTOR—digestive system—malaria	0.00436	0.0494	CbGeAlD
Pimecrolimus—Application site pain—Dapsone—malaria	0.00419	0.016	CcSEcCtD
Pimecrolimus—MTOR—blood—malaria	0.00416	0.0471	CbGeAlD
Pimecrolimus—Application site pain—Clindamycin—malaria	0.00405	0.0154	CcSEcCtD
Pimecrolimus—MTOR—bone marrow—malaria	0.00402	0.0456	CbGeAlD
Pimecrolimus—Application site reaction—Dapsone—malaria	0.00393	0.015	CcSEcCtD
Pimecrolimus—FKBP1A—digestive system—malaria	0.00393	0.0444	CbGeAlD
Pimecrolimus—Bacterial infection—Clindamycin—malaria	0.00386	0.0147	CcSEcCtD
Pimecrolimus—Application site reaction—Clindamycin—malaria	0.0038	0.0145	CcSEcCtD
Pimecrolimus—FKBP1A—blood—malaria	0.00374	0.0423	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—malaria	0.00362	0.041	CbGeAlD
Pimecrolimus—CYP3A4—blood plasma—malaria	0.00334	0.0378	CbGeAlD
Pimecrolimus—MTOR—liver—malaria	0.00325	0.0368	CbGeAlD
Pimecrolimus—FKBP1A—liver—malaria	0.00292	0.0331	CbGeAlD
Pimecrolimus—Folliculitis—Clindamycin—malaria	0.00284	0.0108	CcSEcCtD
Pimecrolimus—Skin discolouration—Sulfadiazine—malaria	0.00265	0.0101	CcSEcCtD
Pimecrolimus—MTOR—brain—malaria	0.00258	0.0292	CbGeAlD
Pimecrolimus—MTOR—TSLP Signaling Pathway—CISH—malaria	0.00255	0.0497	CbGpPWpGaD
Pimecrolimus—FKBP1A—brain—malaria	0.00232	0.0263	CbGeAlD
Pimecrolimus—Skin exfoliation—Sulfadiazine—malaria	0.00228	0.0087	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—malaria	0.00219	0.0428	CbGpPWpGaD
Pimecrolimus—Throat sore—Pentoxifylline—malaria	0.00218	0.00832	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Pentoxifylline—malaria	0.00217	0.00825	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—malaria	0.00213	0.0416	CbGpPWpGaD
Pimecrolimus—Acne—Clindamycin—malaria	0.00212	0.00807	CcSEcCtD
Pimecrolimus—Bone disorder—Quinidine—malaria	0.00194	0.00737	CcSEcCtD
Pimecrolimus—Bone disorder—Quinine—malaria	0.00194	0.00737	CcSEcCtD
Pimecrolimus—CYP3A4—hematopoietic system—malaria	0.00184	0.0209	CbGeAlD
Pimecrolimus—Dermatitis exfoliative—Sulfadiazine—malaria	0.00184	0.00701	CcSEcCtD
Pimecrolimus—Skin exfoliation—Dapsone—malaria	0.00176	0.0067	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—CISH—malaria	0.00175	0.0342	CbGpPWpGaD
Pimecrolimus—Bone disorder—Quinidine barbiturate—malaria	0.00175	0.00665	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Pentoxifylline—malaria	0.00173	0.0066	CcSEcCtD
Pimecrolimus—Skin exfoliation—Clindamycin—malaria	0.0017	0.00648	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Pyrimethamine—malaria	0.00165	0.00629	CcSEcCtD
Pimecrolimus—Immune system disorder—Proguanil—malaria	0.00164	0.00623	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Proguanil—malaria	0.00163	0.00621	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CISH—malaria	0.0016	0.0313	CbGpPWpGaD
Pimecrolimus—Malnutrition—Proguanil—malaria	0.00158	0.006	CcSEcCtD
Pimecrolimus—Erythema—Proguanil—malaria	0.00158	0.006	CcSEcCtD
Pimecrolimus—Influenza like illness—Pentoxifylline—malaria	0.00153	0.00583	CcSEcCtD
Pimecrolimus—CYP3A4—kidney—malaria	0.00151	0.0171	CbGeAlD
Pimecrolimus—Swelling—Clindamycin—malaria	0.00147	0.00559	CcSEcCtD
Pimecrolimus—Cough—Proguanil—malaria	0.00138	0.00524	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Clindamycin—malaria	0.00137	0.00522	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Quinidine—malaria	0.00134	0.00512	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Quinine—malaria	0.00134	0.00512	CcSEcCtD
Pimecrolimus—Ear pain—Pentoxifylline—malaria	0.00134	0.0051	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Proguanil—malaria	0.00133	0.00508	CcSEcCtD
Pimecrolimus—Swelling—Pentoxifylline—malaria	0.0013	0.00494	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—malaria	0.00129	0.0251	CbGpPWpGaD
Pimecrolimus—CYP3A4—digestive system—malaria	0.00128	0.0145	CbGeAlD
Pimecrolimus—Nervous system disorder—Proguanil—malaria	0.00126	0.0048	CcSEcCtD
Pimecrolimus—MTOR—PI3K Cascade—TLR9—malaria	0.00126	0.0246	CbGpPWpGaD
Pimecrolimus—Nasal congestion—Pentoxifylline—malaria	0.00125	0.00478	CcSEcCtD
Pimecrolimus—Skin disorder—Proguanil—malaria	0.00125	0.00476	CcSEcCtD
Pimecrolimus—CYP3A4—blood—malaria	0.00122	0.0138	CbGeAlD
Pimecrolimus—Hypersensitivity—Pyrimethamine—malaria	0.00122	0.00463	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Quinidine barbiturate—malaria	0.00121	0.00462	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Dapsone—malaria	0.0012	0.00455	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Clindamycin—malaria	0.00118	0.0045	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Quinine—malaria	0.00116	0.00441	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Quinidine—malaria	0.00116	0.00441	CcSEcCtD
Pimecrolimus—Influenza—Dapsone—malaria	0.00116	0.0044	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—FCGR2A—malaria	0.00115	0.0225	CbGpPWpGaD
Pimecrolimus—Breast disorder—Quinine—malaria	0.00115	0.00437	CcSEcCtD
Pimecrolimus—Breast disorder—Quinidine—malaria	0.00115	0.00437	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—malaria	0.00114	0.0223	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Proguanil—malaria	0.00111	0.00423	CcSEcCtD
Pimecrolimus—Asthma—Quinine—malaria	0.0011	0.00418	CcSEcCtD
Pimecrolimus—Asthma—Quinidine—malaria	0.0011	0.00418	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Dapsone—malaria	0.00105	0.00402	CcSEcCtD
Pimecrolimus—MTOR—IRS-mediated signalling—TLR9—malaria	0.00105	0.0206	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Proguanil—malaria	0.00105	0.00401	CcSEcCtD
Pimecrolimus—Vomiting—Pyrimethamine—malaria	0.00105	0.004	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Quinidine barbiturate—malaria	0.00105	0.00398	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Clindamycin—malaria	0.00104	0.00396	CcSEcCtD
Pimecrolimus—Breast disorder—Quinidine barbiturate—malaria	0.00103	0.00394	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—TLR9—malaria	0.00103	0.02	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Clindamycin—malaria	0.00102	0.00389	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—TLR9—malaria	0.00102	0.0199	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Proguanil—malaria	0.00102	0.00387	CcSEcCtD
Pimecrolimus—Abdominal pain—Proguanil—malaria	0.00102	0.00387	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Quinine—malaria	0.001	0.00381	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Quinidine—malaria	0.001	0.00381	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—TLR9—malaria	0.00099	0.0193	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—TLR9—malaria	0.00099	0.0193	CbGpPWpGaD
Pimecrolimus—Asthma—Quinidine barbiturate—malaria	0.00099	0.00377	CcSEcCtD
Pimecrolimus—Sinusitis—Dapsone—malaria	0.000967	0.00368	CcSEcCtD
Pimecrolimus—CYP3A4—liver—malaria	0.000956	0.0108	CbGeAlD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL12B—malaria	0.000942	0.0184	CbGpPWpGaD
Pimecrolimus—Epistaxis—Clindamycin—malaria	0.00094	0.00358	CcSEcCtD
Pimecrolimus—Pharyngitis—Dapsone—malaria	0.000918	0.0035	CcSEcCtD
Pimecrolimus—MTOR—SREBP signalling—SCARB1—malaria	0.000915	0.0179	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Quinidine barbiturate—malaria	0.000903	0.00344	CcSEcCtD
Pimecrolimus—Arthralgia—Sulfadiazine—malaria	0.000891	0.00339	CcSEcCtD
Pimecrolimus—Infestation NOS—Pentoxifylline—malaria	0.000881	0.00336	CcSEcCtD
Pimecrolimus—Infestation—Pentoxifylline—malaria	0.000881	0.00336	CcSEcCtD
Pimecrolimus—Diarrhoea—Proguanil—malaria	0.00088	0.00335	CcSEcCtD
Pimecrolimus—Conjunctivitis—Pentoxifylline—malaria	0.000856	0.00326	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Sulfadiazine—malaria	0.000854	0.00325	CcSEcCtD
Pimecrolimus—Epistaxis—Pentoxifylline—malaria	0.000831	0.00317	CcSEcCtD
Pimecrolimus—Flushing—Clindamycin—malaria	0.000831	0.00316	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—TLR9—malaria	0.000823	0.0161	CbGpPWpGaD
Pimecrolimus—Eye disorder—Quinine—malaria	0.00082	0.00313	CcSEcCtD
Pimecrolimus—Eye disorder—Quinidine—malaria	0.00082	0.00313	CcSEcCtD
Pimecrolimus—Vomiting—Proguanil—malaria	0.000818	0.00312	CcSEcCtD
Pimecrolimus—Flushing—Quinine—malaria	0.000815	0.0031	CcSEcCtD
Pimecrolimus—Flushing—Quinidine—malaria	0.000815	0.0031	CcSEcCtD
Pimecrolimus—Rash—Proguanil—malaria	0.000811	0.00309	CcSEcCtD
Pimecrolimus—Dermatitis—Proguanil—malaria	0.00081	0.00309	CcSEcCtD
Pimecrolimus—Headache—Proguanil—malaria	0.000806	0.00307	CcSEcCtD
Pimecrolimus—Erythema—Dapsone—malaria	0.000805	0.00307	CcSEcCtD
Pimecrolimus—Immune system disorder—Quinidine—malaria	0.000793	0.00302	CcSEcCtD
Pimecrolimus—Immune system disorder—Quinine—malaria	0.000793	0.00302	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Quinine—malaria	0.000791	0.00301	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Quinidine—malaria	0.000791	0.00301	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—HPGDS—malaria	0.000785	0.0153	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—malaria	0.000783	0.0153	CbGpPWpGaD
Pimecrolimus—Erythema—Clindamycin—malaria	0.000779	0.00297	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Sulfadiazine—malaria	0.000778	0.00296	CcSEcCtD
Pimecrolimus—Erythema—Quinine—malaria	0.000764	0.00291	CcSEcCtD
Pimecrolimus—Erythema—Quinidine—malaria	0.000764	0.00291	CcSEcCtD
Pimecrolimus—Malnutrition—Quinidine—malaria	0.000764	0.00291	CcSEcCtD
Pimecrolimus—Malnutrition—Quinine—malaria	0.000764	0.00291	CcSEcCtD
Pimecrolimus—Nausea—Proguanil—malaria	0.000764	0.00291	CcSEcCtD
Pimecrolimus—Back pain—Clindamycin—malaria	0.000754	0.00287	CcSEcCtD
Pimecrolimus—Eye disorder—Quinidine barbiturate—malaria	0.00074	0.00282	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Sulfadiazine—malaria	0.000737	0.00281	CcSEcCtD
Pimecrolimus—Flushing—Quinidine barbiturate—malaria	0.000735	0.0028	CcSEcCtD
Pimecrolimus—Flushing—Pentoxifylline—malaria	0.000734	0.0028	CcSEcCtD
Pimecrolimus—Immune system disorder—Quinidine barbiturate—malaria	0.000716	0.00273	CcSEcCtD
Pimecrolimus—Immune system disorder—Pentoxifylline—malaria	0.000714	0.00272	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Quinidine barbiturate—malaria	0.000714	0.00272	CcSEcCtD
Pimecrolimus—Cough—Dapsone—malaria	0.000703	0.00268	CcSEcCtD
Pimecrolimus—Angioedema—Quinine—malaria	0.000698	0.00266	CcSEcCtD
Pimecrolimus—Angioedema—Quinidine—malaria	0.000698	0.00266	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Sulfadiazine—malaria	0.000698	0.00266	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL4—malaria	0.000693	0.0135	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL18—malaria	0.000691	0.0135	CbGpPWpGaD
Pimecrolimus—Malnutrition—Quinidine barbiturate—malaria	0.00069	0.00263	CcSEcCtD
Pimecrolimus—Erythema—Quinidine barbiturate—malaria	0.00069	0.00263	CcSEcCtD
Pimecrolimus—Erythema—Pentoxifylline—malaria	0.000688	0.00262	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—malaria	0.000681	0.0133	CbGpPWpGaD
Pimecrolimus—Urticaria—Sulfadiazine—malaria	0.000678	0.00258	CcSEcCtD
Pimecrolimus—Abdominal pain—Sulfadiazine—malaria	0.000675	0.00257	CcSEcCtD
Pimecrolimus—Body temperature increased—Sulfadiazine—malaria	0.000675	0.00257	CcSEcCtD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL10—malaria	0.000671	0.0131	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CD40LG—malaria	0.000671	0.0131	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL4—malaria	0.00067	0.0131	CbGpPWpGaD
Pimecrolimus—Back pain—Pentoxifylline—malaria	0.000666	0.00254	CcSEcCtD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL4—malaria	0.000652	0.0127	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Quinidine—malaria	0.000646	0.00246	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Quinine—malaria	0.000646	0.00246	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Clindamycin—malaria	0.000636	0.00242	CcSEcCtD
Pimecrolimus—Angioedema—Quinidine barbiturate—malaria	0.00063	0.0024	CcSEcCtD
Pimecrolimus—Angioedema—Pentoxifylline—malaria	0.000629	0.0024	CcSEcCtD
Pimecrolimus—Hypersensitivity—Sulfadiazine—malaria	0.000629	0.0024	CcSEcCtD
Pimecrolimus—Oedema—Quinidine—malaria	0.000624	0.00238	CcSEcCtD
Pimecrolimus—Oedema—Quinine—malaria	0.000624	0.00238	CcSEcCtD
Pimecrolimus—Nervous system disorder—Quinine—malaria	0.000612	0.00233	CcSEcCtD
Pimecrolimus—Nervous system disorder—Quinidine—malaria	0.000612	0.00233	CcSEcCtD
Pimecrolimus—Skin disorder—Quinidine—malaria	0.000606	0.00231	CcSEcCtD
Pimecrolimus—Skin disorder—Quinine—malaria	0.000606	0.00231	CcSEcCtD
Pimecrolimus—Pruritus—Sulfadiazine—malaria	0.000604	0.0023	CcSEcCtD
Pimecrolimus—Arthralgia—Quinidine barbiturate—malaria	0.000587	0.00224	CcSEcCtD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—malaria	0.000585	0.0114	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Sulfadiazine—malaria	0.000584	0.00223	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Quinidine barbiturate—malaria	0.000583	0.00222	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—malaria	0.000582	0.00222	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TLR4—malaria	0.000574	0.0112	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—ICAM1—malaria	0.00057	0.0111	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Quinine—malaria	0.000568	0.00216	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Quinidine—malaria	0.000568	0.00216	CcSEcCtD
Pimecrolimus—Dyspnoea—Clindamycin—malaria	0.000567	0.00216	CcSEcCtD
Pimecrolimus—Oedema—Quinidine barbiturate—malaria	0.000563	0.00214	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Pentoxifylline—malaria	0.000562	0.00214	CcSEcCtD
Pimecrolimus—Oedema—Pentoxifylline—malaria	0.000562	0.00214	CcSEcCtD
Pimecrolimus—Infection—Pentoxifylline—malaria	0.000558	0.00213	CcSEcCtD
Pimecrolimus—Dyspnoea—Quinine—malaria	0.000556	0.00212	CcSEcCtD
Pimecrolimus—Dyspnoea—Quinidine—malaria	0.000556	0.00212	CcSEcCtD
Pimecrolimus—Nervous system disorder—Quinidine barbiturate—malaria	0.000552	0.0021	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—ICAM1—malaria	0.000551	0.0108	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Clindamycin—malaria	0.000549	0.00209	CcSEcCtD
Pimecrolimus—Skin disorder—Quinidine barbiturate—malaria	0.000547	0.00208	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—NOS2—malaria	0.000546	0.0107	CbGpPWpGaD
Pimecrolimus—Skin disorder—Pentoxifylline—malaria	0.000546	0.00208	CcSEcCtD
Pimecrolimus—Pain—Clindamycin—malaria	0.000544	0.00207	CcSEcCtD
Pimecrolimus—Constipation—Clindamycin—malaria	0.000544	0.00207	CcSEcCtD
Pimecrolimus—Vomiting—Sulfadiazine—malaria	0.000543	0.00207	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Quinidine—malaria	0.000538	0.00205	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Quinine—malaria	0.000538	0.00205	CcSEcCtD
Pimecrolimus—Rash—Sulfadiazine—malaria	0.000538	0.00205	CcSEcCtD
Pimecrolimus—Dermatitis—Sulfadiazine—malaria	0.000538	0.00205	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dapsone—malaria	0.000537	0.00205	CcSEcCtD
Pimecrolimus—Headache—Sulfadiazine—malaria	0.000535	0.00204	CcSEcCtD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—malaria	0.00053	0.0103	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IFNG—malaria	0.000528	0.0103	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—NOS2—malaria	0.000528	0.0103	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Clindamycin—malaria	0.00052	0.00198	CcSEcCtD
Pimecrolimus—Abdominal pain—Dapsone—malaria	0.00052	0.00198	CcSEcCtD
Pimecrolimus—Body temperature increased—Dapsone—malaria	0.00052	0.00198	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Quinidine barbiturate—malaria	0.000513	0.00195	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Pentoxifylline—malaria	0.000512	0.00195	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Quinidine—malaria	0.00051	0.00194	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Quinine—malaria	0.00051	0.00194	CcSEcCtD
Pimecrolimus—Nausea—Sulfadiazine—malaria	0.000507	0.00193	CcSEcCtD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—malaria	0.000507	0.0099	CbGpPWpGaD
Pimecrolimus—Urticaria—Clindamycin—malaria	0.000505	0.00192	CcSEcCtD
Pimecrolimus—Body temperature increased—Clindamycin—malaria	0.000503	0.00191	CcSEcCtD
Pimecrolimus—Abdominal pain—Clindamycin—malaria	0.000503	0.00191	CcSEcCtD
Pimecrolimus—Dyspnoea—Quinidine barbiturate—malaria	0.000502	0.00191	CcSEcCtD
Pimecrolimus—Dyspnoea—Pentoxifylline—malaria	0.000501	0.00191	CcSEcCtD
Pimecrolimus—Urticaria—Quinine—malaria	0.000495	0.00189	CcSEcCtD
Pimecrolimus—Urticaria—Quinidine—malaria	0.000495	0.00189	CcSEcCtD
Pimecrolimus—Body temperature increased—Quinine—malaria	0.000493	0.00188	CcSEcCtD
Pimecrolimus—Abdominal pain—Quinidine—malaria	0.000493	0.00188	CcSEcCtD
Pimecrolimus—Body temperature increased—Quinidine—malaria	0.000493	0.00188	CcSEcCtD
Pimecrolimus—Abdominal pain—Quinine—malaria	0.000493	0.00188	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Quinidine barbiturate—malaria	0.000486	0.00185	CcSEcCtD
Pimecrolimus—Pain—Quinidine barbiturate—malaria	0.000481	0.00183	CcSEcCtD
Pimecrolimus—Constipation—Quinidine barbiturate—malaria	0.000481	0.00183	CcSEcCtD
Pimecrolimus—Constipation—Pentoxifylline—malaria	0.00048	0.00183	CcSEcCtD
Pimecrolimus—MTOR—IFN-gamma pathway—IL1B—malaria	0.000471	0.0092	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Clindamycin—malaria	0.000468	0.00178	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Quinidine barbiturate—malaria	0.00046	0.00175	CcSEcCtD
Pimecrolimus—Hypersensitivity—Quinidine—malaria	0.00046	0.00175	CcSEcCtD
Pimecrolimus—Hypersensitivity—Quinine—malaria	0.00046	0.00175	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Pentoxifylline—malaria	0.000459	0.00175	CcSEcCtD
Pimecrolimus—Pruritus—Clindamycin—malaria	0.00045	0.00171	CcSEcCtD
Pimecrolimus—Urticaria—Quinidine barbiturate—malaria	0.000447	0.0017	CcSEcCtD
Pimecrolimus—Urticaria—Pentoxifylline—malaria	0.000446	0.0017	CcSEcCtD
Pimecrolimus—Abdominal pain—Quinidine barbiturate—malaria	0.000445	0.00169	CcSEcCtD
Pimecrolimus—Body temperature increased—Quinidine barbiturate—malaria	0.000445	0.00169	CcSEcCtD
Pimecrolimus—Abdominal pain—Pentoxifylline—malaria	0.000444	0.00169	CcSEcCtD
Pimecrolimus—Body temperature increased—Pentoxifylline—malaria	0.000444	0.00169	CcSEcCtD
Pimecrolimus—Pruritus—Quinine—malaria	0.000441	0.00168	CcSEcCtD
Pimecrolimus—Pruritus—Quinidine—malaria	0.000441	0.00168	CcSEcCtD
Pimecrolimus—Diarrhoea—Clindamycin—malaria	0.000435	0.00166	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—malaria	0.000435	0.00849	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Quinidine—malaria	0.000427	0.00163	CcSEcCtD
Pimecrolimus—Diarrhoea—Quinine—malaria	0.000427	0.00163	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IFNG—malaria	0.000419	0.00818	CbGpPWpGaD
Pimecrolimus—Vomiting—Dapsone—malaria	0.000418	0.00159	CcSEcCtD
Pimecrolimus—Hypersensitivity—Quinidine barbiturate—malaria	0.000415	0.00158	CcSEcCtD
Pimecrolimus—Hypersensitivity—Pentoxifylline—malaria	0.000414	0.00158	CcSEcCtD
Pimecrolimus—Headache—Dapsone—malaria	0.000412	0.00157	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—IFNG—malaria	0.000405	0.0079	CbGpPWpGaD
Pimecrolimus—Vomiting—Clindamycin—malaria	0.000404	0.00154	CcSEcCtD
Pimecrolimus—Rash—Clindamycin—malaria	0.000401	0.00153	CcSEcCtD
Pimecrolimus—Dermatitis—Clindamycin—malaria	0.0004	0.00153	CcSEcCtD
Pimecrolimus—Headache—Clindamycin—malaria	0.000398	0.00152	CcSEcCtD
Pimecrolimus—Pruritus—Quinidine barbiturate—malaria	0.000398	0.00152	CcSEcCtD
Pimecrolimus—Pruritus—Pentoxifylline—malaria	0.000398	0.00151	CcSEcCtD
Pimecrolimus—Vomiting—Quinidine—malaria	0.000397	0.00151	CcSEcCtD
Pimecrolimus—Vomiting—Quinine—malaria	0.000397	0.00151	CcSEcCtD
Pimecrolimus—Rash—Quinidine—malaria	0.000393	0.0015	CcSEcCtD
Pimecrolimus—Rash—Quinine—malaria	0.000393	0.0015	CcSEcCtD
Pimecrolimus—Dermatitis—Quinidine—malaria	0.000393	0.0015	CcSEcCtD
Pimecrolimus—Dermatitis—Quinine—malaria	0.000393	0.0015	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—malaria	0.000391	0.00763	CbGpPWpGaD
Pimecrolimus—Headache—Quinine—malaria	0.000391	0.00149	CcSEcCtD
Pimecrolimus—Headache—Quinidine—malaria	0.000391	0.00149	CcSEcCtD
Pimecrolimus—Nausea—Dapsone—malaria	0.00039	0.00149	CcSEcCtD
Pimecrolimus—Diarrhoea—Quinidine barbiturate—malaria	0.000385	0.00147	CcSEcCtD
Pimecrolimus—Diarrhoea—Pentoxifylline—malaria	0.000384	0.00146	CcSEcCtD
Pimecrolimus—Nausea—Clindamycin—malaria	0.000378	0.00144	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL1B—malaria	0.000374	0.0073	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL2—malaria	0.000372	0.00727	CbGpPWpGaD
Pimecrolimus—Nausea—Quinidine—malaria	0.00037	0.00141	CcSEcCtD
Pimecrolimus—Nausea—Quinine—malaria	0.00037	0.00141	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—IFNG—malaria	0.000366	0.00715	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL1B—malaria	0.000361	0.00705	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL2—malaria	0.00036	0.00702	CbGpPWpGaD
Pimecrolimus—Vomiting—Quinidine barbiturate—malaria	0.000358	0.00136	CcSEcCtD
Pimecrolimus—Vomiting—Pentoxifylline—malaria	0.000357	0.00136	CcSEcCtD
Pimecrolimus—Rash—Quinidine barbiturate—malaria	0.000355	0.00135	CcSEcCtD
Pimecrolimus—Dermatitis—Quinidine barbiturate—malaria	0.000355	0.00135	CcSEcCtD
Pimecrolimus—Rash—Pentoxifylline—malaria	0.000354	0.00135	CcSEcCtD
Pimecrolimus—Dermatitis—Pentoxifylline—malaria	0.000354	0.00135	CcSEcCtD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—malaria	0.000354	0.00691	CbGpPWpGaD
Pimecrolimus—Headache—Quinidine barbiturate—malaria	0.000353	0.00134	CcSEcCtD
Pimecrolimus—Headache—Pentoxifylline—malaria	0.000352	0.00134	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—KDR—malaria	0.000349	0.00682	CbGpPWpGaD
Pimecrolimus—Nausea—Quinidine barbiturate—malaria	0.000334	0.00127	CcSEcCtD
Pimecrolimus—Nausea—Pentoxifylline—malaria	0.000334	0.00127	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—KDR—malaria	0.00033	0.00644	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IL2—malaria	0.000325	0.00636	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FCGR2B—malaria	0.000311	0.00607	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—IL1B—malaria	0.000302	0.0059	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—malaria	0.000299	0.00583	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TIRAP—malaria	0.000288	0.00563	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—malaria	0.000281	0.00549	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HLA-B—malaria	0.000276	0.00538	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—malaria	0.000271	0.0053	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CR1—malaria	0.000268	0.00523	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—malaria	0.000259	0.00505	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—malaria	0.000257	0.00502	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PKLR—malaria	0.000256	0.00501	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—malaria	0.000231	0.00451	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—G6PD—malaria	0.000228	0.00446	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR9—malaria	0.000228	0.00445	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—malaria	0.000219	0.00427	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—malaria	0.0002	0.00391	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CISH—malaria	0.0002	0.0039	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ACKR1—malaria	0.000189	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FCGR2B—malaria	0.000188	0.00368	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—malaria	0.000184	0.0036	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FCGR2A—malaria	0.000182	0.00356	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TIRAP—malaria	0.000168	0.00328	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—DHFR—malaria	0.000162	0.00316	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—malaria	0.00016	0.00312	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CR1—malaria	0.000156	0.00305	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—malaria	0.000156	0.00304	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—malaria	0.000154	0.00301	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TLR9—malaria	0.000153	0.00298	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—malaria	0.00015	0.00293	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—malaria	0.00015	0.00293	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PKLR—malaria	0.000144	0.00281	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—malaria	0.000135	0.00264	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—malaria	0.000133	0.0026	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR9—malaria	0.000133	0.00259	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—G6PD—malaria	0.000128	0.00251	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—HPGDS—malaria	0.000127	0.00249	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—malaria	0.000126	0.00245	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—malaria	0.000125	0.00244	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—malaria	0.000108	0.00211	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HLA-B—malaria	0.000107	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—malaria	0.000107	0.00209	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—malaria	0.000107	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ACKR1—malaria	0.000106	0.00208	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FCGR2A—malaria	0.000106	0.00207	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD36—malaria	0.000105	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-B—malaria	0.000103	0.00201	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—malaria	0.000102	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD36—malaria	0.000101	0.00197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—malaria	0.000101	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—malaria	9.6e-05	0.00187	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—malaria	9.55e-05	0.00187	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—malaria	9.51e-05	0.00186	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CRP—malaria	9.47e-05	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—malaria	9.46e-05	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—DHFR—malaria	9.09e-05	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—malaria	9.07e-05	0.00177	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—malaria	8.9e-05	0.00174	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—malaria	8.9e-05	0.00174	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—malaria	8.9e-05	0.00174	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—malaria	8.82e-05	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—malaria	8.74e-05	0.00171	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—malaria	8.7e-05	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TLR9—malaria	8.58e-05	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ICAM1—malaria	8.35e-05	0.00163	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS2—malaria	8.25e-05	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—malaria	7.88e-05	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL18—malaria	6.58e-05	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—malaria	6.56e-05	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—malaria	6.48e-05	0.00127	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—malaria	6.46e-05	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—malaria	6.39e-05	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-B—malaria	6.24e-05	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—malaria	6.14e-05	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD36—malaria	6.12e-05	0.00119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—malaria	6.11e-05	0.00119	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—malaria	6.08e-05	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—malaria	6.06e-05	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CRP—malaria	5.51e-05	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—malaria	5.29e-05	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ICAM1—malaria	5.07e-05	0.000989	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DHODH—malaria	4.97e-05	0.00097	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS2—malaria	4.64e-05	0.000906	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC4A1—malaria	4.23e-05	0.000825	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DECR1—malaria	3.97e-05	0.000776	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—malaria	3.94e-05	0.000769	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—malaria	3.86e-05	0.000753	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—malaria	3.72e-05	0.000727	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HBB—malaria	3.59e-05	0.000702	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—malaria	3.46e-05	0.000675	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—malaria	3.44e-05	0.000672	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—malaria	3.44e-05	0.000671	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—malaria	3.43e-05	0.000669	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—malaria	3.42e-05	0.000667	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—malaria	3.31e-05	0.000646	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PKLR—malaria	3.2e-05	0.000625	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—G6PD—malaria	2.85e-05	0.000557	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—malaria	2.32e-05	0.000452	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—malaria	2.22e-05	0.000433	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—malaria	2.18e-05	0.000425	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DHFR—malaria	2.02e-05	0.000394	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—malaria	2.01e-05	0.000393	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SCARB1—malaria	2e-05	0.00039	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—malaria	1.86e-05	0.000363	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—malaria	1.3e-05	0.000254	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD36—malaria	1.25e-05	0.000245	CbGpPWpGaD
